Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase II trial of dose dense neo-adjuvant gemcitabine, epirubicin, ABI-007 [paclitaxel] (GEA) in locally advanced or inflammatory breast cancer.

Next Previous
Trial Profile

Phase II trial of dose dense neo-adjuvant gemcitabine, epirubicin, ABI-007 [paclitaxel] (GEA) in locally advanced or inflammatory breast cancer.

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 24 Nov 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Epirubicin (Primary) ; Gemcitabine (Primary) ; Paclitaxel (Primary) ; Pegfilgrastim (Primary)
  • Indications Advanced breast cancer
  • Focus Therapeutic Use

Most Recent Events

  • 02 May 2011 Celgene Corporation as company and lead trial centre added as reported by ClinicalTrials.gov.
  • 23 Jun 2009 Actual end date (May 2009) added as reported by ClinicalTrials.gov.
  • 23 Jun 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top